Vivus (vvus) Stock Research
Last Updated by WikiWealth | Update This Page Now
Generic strategies categorize companies by the scope and the strength of their business. Vivus does not have a definable strategy, therefore, it risks losing out to firms that concentrate on one particular competitive advantage. (read more).
Company Description: VIVUS, Inc., founded in 1991, is a pharmaceutical company that develops therapeutic products for underserved markets in the United States. Products include a minimally invasive therapy for erectile dysfunction, as well as clinical products for obesity, diabetes, and sexual health. in men and women. VIVUS is headquartered in Mountain View, California. Update
Health Care Industry Research & Analysis: The health care industry depends on the care of health-related services by professionals for the benefit of patients. Medical device markers, insurance companies, pharmaceutical drug developers and government institutions are major participants in the treatment of sick, injured and disabled patients. Health Care Trading Strategy: Health Care stocks tend to be less sensitive to economic changes. Look for undervalued health care investments at any point in the business cycle when stock prices are low. However, biotech, employment staffing and insurance companies may all decrease during recessions for different reasons. Government intervention is another important factor in health care investments, since government spending in health care is a very large portion of overall health care spending. When governments change spending plans, different sub-sectors in the industry are significantly affected. Upward sloping stock charts and financial news may indicate a selling opportunity while the opposite means that stocks are becoming undervalued.
Industry Sub Sector: .
Market Challenges: Opportunities: Solutions:
Vivus's strategy is to continuously improve. This helps to fend against competitive threats and increases shareholder returns.
Strategy: Competitive Advantages:
Current Revenue Sources: Future Revenue Sources: